Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS

Authors: A Plettenberg, NH Brockmeyer, B Haastert, S Dupke, CK Schewe, M Rausch, M Hower, G Arendt, K Jansen, HIV KompNet

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

Optimal time of HAART initiation is still unknown. Several studies investigating this issue showed inconsistent results. Our study investigated whether there is a clinical benefit as to treated patients (pts) by an earlier start of therapy at CD4 between 350-449c/µl, compared to the range of 250-349c/µl. An analysis was conducted on basis of the open, retrospective and prospective, multi-center and nationwide cohort of the Competence Network for HIV/AIDS. …
Metadata
Title
Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS
Authors
A Plettenberg
NH Brockmeyer
B Haastert
S Dupke
CK Schewe
M Rausch
M Hower
G Arendt
K Jansen
HIV KompNet
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P16

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue

Oral presentation

O212. Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis

Poster presentation

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1

Poster presentation

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL

Poster presentation

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

Poster presentation

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

Poster presentation

Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits